Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 195   

Articles published

VRX 16.40 +0.36 (2.24%)
price chart
Is Valeant Pharmaceuticals Intl Inc. “Investable?”
While the quick answer to this seemingly straightforward question might be a resounding “no,” thanks to Valeant's scandalous history and $30 billion worth of debt on US$5.4 billion market cap, there are three positive factors of Valeant that make it ...
Stock Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Signs Licensing ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, ...
UPDATED: EyeGate Pharma surges 49% on news of $4 million Valeant licensing ...  MarketWatch
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) And Valeant Pharmaceuticals Intl ...  Journal Transcript
How 2017 Will Unfold for Valeant Pharmaceuticals Intl Inc.
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) took a hammering last year. The stock lost over 85% value over the course of the year.
Shares of Valeant Pharmaceuticals International, Inc. (VRX) Sees Large ...  Highland Mirror
Tocqueville Asset Management LP Raises Stake in Valeant Pharmaceuticals ...  Sports Perspectives
Valeant Pharmaceuticals Intl Inc.: Should You Take a Contrarian Shot?
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is now trading at lows not seen in more than six years. Let's take a look at the troubled Canadian drug company to see if the sell-off looks overdone.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shows optimistic Trends  TopChronicle
Valeant Pharmaceuticals International, Inc. (VRX) Stock Rating Lowered by ...  Sports Perspectives
What Could Go Right for Valeant Pharmaceutical Intl Inc.?
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been struggling to sustain a rally back to higher levels, even over a year after the negative press that sent the stock tumbling by over 90%.
Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Due for More Punishment
Barclays Just Issued “Equal Weight” Rating on Valeant Pharmaceuticals Intl ...  Highland Mirror
Valeant Pharmaceuticals Intl Inc. Crushed by Citron Research: Find Out Who's Next
For short-sellers looking for another opportunity to capitalize on accounting manipulations and scandals to reap a massive pay day, as with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), Andrew Left from Citron Research has another top pick for ...
Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Finally Stabilize  Nasdaq
What to Look for When Valeant Pharmaceuticals Intl Inc (VRX) Reports Earnings  Smarter Analyst
Valeant: Price Target Over $30
A stock typically signals severe undervaluation when the company reports positive developments but the stock barely moves. When Valeant Pharmaceuticals (NYSE:VRX) reports quarterly results, a higher outlook from CEO Joe Papa may put an end to the ...
Valeant Pharmaceuticals Intl Inc (VRX): What This Top Analyst Is Saying
Though Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were surging nicely ahead at almost 6% yesterday, and continuing to rise today, top analyst Irina Rivkind Koffler at Mizuho remains bearish on the stock.
Valeant Pharmaceuticals International Inc. (VRX:CA) Rises 5.56% for February 15
Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still in Trouble
Chris Davis' 4Q Investment Spotlight: Valeant Pharmaceuticals Intl Inc (VRX ...
This approach makes it particularly interesting to examine three of Davis' most intriguing Q4 portfolio moves, he reduced holdings in both Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and, Inc. (NASDAQ:AMZN), while making a substantial ...
Is Siliq A New Beginning For Valeant?
Unlike the divestitures, a new asset provides value that will stick in the stock price because, as mentioned earlier, much of Valeant's value will depend on its growth potential. The debt doesn't matter nearly as much as many think. Many market ...
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe ...  PR Newswire (press release)
Valeant stock surges 3% after psoriasis drug gets FDA approval  MarketWatch